معرفی
Hardev Pandha is a Professor of Medical Oncology at the University of Surrey, affiliated with the School of Biosciences within the Faculty of Health and Medical Sciences. He specializes in urological oncology and medical oncology, with a focus on translational research in cancer immunotherapy and virotherapy. His clinical and academic career includes roles at institutions such as the Royal Postgraduate Medical School at Hammersmith Hospital, Royal Marsden Hospital, and St George's, University of London. His research explores innovative treatments like oncolytic viruses (e.g., coxsackievirus A21) for bladder cancer, genetic risk assessment for prostate cancer, and immunotherapeutic strategies to combat cancer progression. Key projects include a Phase II trial of a modified vaccinia Ankara-5T4 vaccine for ovarian cancer and studies on EN2 protein as a bladder cancer biomarker. Pandha collaborates internationally, with work published in high-impact journals. His research aims to improve cancer diagnosis, treatment efficacy, and patient outcomes through cutting-edge molecular and immunological approaches.
Educational Background
- Bachelor of Medicine, University of Birmingham
- PhD in Molecular Oncology (Imperial College London), conducted at Imperial Cancer Research Fund labs
- Visiting Fellowship at Stanford University
Research Interests
Pandha’s work spans:
- Virotherapy: Using coxsackievirus to target bladder cancer with minimal side effects
- Immunotherapy: Enhancing anti-tumor immunity via combination therapies (e.g., checkpoint inhibitors, histone deacetylase inhibitors)
- Genetic Risk Modeling: Developing polygenic hazard scores to predict prostate cancer progression
- Molecular Diagnostics: Identifying biomarkers like EN2 protein for early cancer detection
- Cancer Biology: Investigating neuroendocrine transdifferentiation in prostate cancer
Grants & Collaborations
Pandha leads UK-wide clinical trials and collaborates with institutions like Waters Corporation on translational research. His work has been funded by organizations such as Viralytics Ltd and the UK Biobank.
Labs & Teams
He oversees research teams focused on oncology translational medicine, viroimmunology, and molecular diagnostics within the University of Surrey’s School of Biosciences. His lab investigates tumor microenvironment dynamics and microbiome interactions in bladder cancer.
